











was first reported. While some of these drugs are still used such as dexamethasone, the use of some drugs has been stopped. The long-term course of the disease, its complications, and the long-term effects of the drugs used are unknown. Perhaps, the currently used treatment protocols may not be used over time, or dose changes may be made in drugs. In our systematic review, 10 patients with G6PD deficiency treated with HCQ/CQ for COVID-19 infection were examined. The common characteristics of the participants were as follows: hemolysis, male gender, ethnic regions where G6PD deficiency is more common, and absence of a previous history of hemolytic anemia. Hemolysis developed in patients independently of the amount of HCQ/CQ used. We think that it would be beneficial to limit the use of HCQ/CQ in patients infected with COVID-19, especially in those with ethnic origins of Africa, Asia, Mediterranean coasts, with male gender. However, there is a need for further retrospective and prospective studies including more data on the subject.

#### DISCLOSURE

The authors have no conflict of interest.

#### REFERENCES

- Frosch T, Schmitt M, Bringmann G, Kiefer W, Popp J (2007) Structural Analysis of the Anti-Malaria Active Agent Chloroquine under Physiological Conditions. *J Phys Chem B* 111(7): 1815-1822.
- Fan HH, Wang LQ, Liu WL, An XP, Liu ZD, et al. (202) Repurposing of Clinically Approved Drugs for Treatment of Coronavirus Disease 2019 in a 2019-novel Coronavirus-Related Coronavirus Model. *Chinese Med J* 133(9): 1051-1056.
- Lei ZN, Wu ZX, Dong S, Yang DH, Zhang L, et al. (2020) Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. *Pharmacol Ther* 216: 107672.
- Afra TP, Nampoothiri RV, Razmi TM, Bishurul Hafi NAB (2020) Linking hydroxychloroquine to hemolysis in a "suspected" glucose 6 phosphate dehydrogenase deficient patient with COVID-19 infection-a critical appraisal. *Eur J Intern Med* 80: 101-102.
- Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents* 56(1): 105949.
- Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, et al. (2020) The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. *Nature Med* 26(6): 808-809.
- Beauverd Y, Adam Y, Assouline B, Samii K (2020) COVID-19 infection and treatment with hydroxychloroquine cause severe hemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency. *Eur J Haematol* 105(3): 357-359.
- Maillart E, Leemans S, Noten HV, Vandergraesen T, Mahadeb B, et al. (2020) A case report of serious hemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. *Infect Dis (Lond)* 52(9): 659-661.
- Chaney S, Basirat A, McDermott R, Keenan N, Moloney E (2020) COVID-19 & Hydroxychloroquine side-effects: Glucose 6-phosphate dehydrogenase deficiency (G6PD) and acute hemolytic anemia. *Int J Med* 113(12): 890-891.
- Sasi S, Yassin MA, Nair AP, Al Maslamani MS (2020) A Case of COVID-19 in a Patient with Asymptomatic Hemoglobin D Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency. *Am J Case Rep* 21: e925788.
- Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency. Accessed on: May 20, 2021. Available online at: <https://emedicine.medscape.com/article/200390-overview#a5>
- Biodiagnostic, Diagnostic and Research Reagents (2021) Glucose-6-Phosphate Dehydrogenase.
- Naymagon L, Berwick S, Kessler A, Lancman G, Gidwani U (2020). The emergence of methemoglobinemia amidst the COVID-19 pandemic. *Am J Hematol* 95(8): 196-197.
- Franceschia L, Costab E, Dimad F, Morandia M, Olivieria O (2020) Acute hemolysis by hydroxychloroquine was observed in G6PD-deficient patient with severe COVID-19 related lung injury. *Eur J Internal Med* 77: 136-137.
- Mastroianni F, Colombie V, Claes G, Gilles A, Vanderghyest F (2020). Hydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Hemolytic Anemia: Culprit or Innocent Bystander? *Eur J Case Rep Internal Med* 7(9): 1-3.
- Kuipers MT, Zwieten R, Heijmans J, Rutten CE, Heer K (2020) G6PD deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine. *Am J Hematol* 95(8): 194-196.
- Obeidat K, Yassin MA (2020) Can Hydroxychloroquine Cause G6PD-Related Hemolysis? A Case Study. *Dubai Med J* 3(4): 140-142.
- Lim S, Bhatia K, Lee Y (2020) Hemolytic Anemia and Methemoglobinemia Due to Hydroxychloroquine Use for Covid-19 Treatment in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient. *Chest* 158(4): 558-559.

19. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group.
20. Franceschia L, Costab E, Dimad F, Morandia M, Olivieria O (2020) Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out. *Eur J Internal Med* 80: 103.
21. EUA (2020) Hydroxychloroquine sulfate Health Care Provider Fact Sheet, version date 4/27/2020. Available online at: <https://www.fda.gov/media/136537/download>
22. USFDA (2020) Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Accessed on: May 17, 2021. Available online at: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and>
23. USFDA (2021) Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Accessed on: June 19, 2021. Available online at: <https://www.covid19treatmentguidelines.nih.gov/>
24. Zuchelkowski BE, Wang L, Gingras S, Xu Q, Yang M (2020) Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a “humanized” G6PD A- mouse model. *PLoS One* 15(10): e0240266.
25. Mohammed S, Clowse MEB, Eudry A, Criscione-Schreiber L (2020) Hydroxychloroquine is not associated with hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency. *Eur J Haematol* 105(3): 357-359.
26. Onori ME, Ricciardi Tenore C, Urbani A, Minucci A (2021) Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: A mini review. *Mol Biol Rep* 48(3): 2973-2978.
27. Yang HC, Ma TH, Tjong WY, Stern A, Chiu DTY (2021) G6PD deficiency, redox homeostasis, and viral infections: implications for SARS-CoV-2 (COVID-19). *Free Radic Res* 54(11-12): 1-12.
28. Al-Sweedan SA, Jdaitawi H, Khriesat WM, Khader YY, AlRimawi HS (2009) Predictors of severe hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency following exposure to oxidant stresses. *Hematol Oncol Stem Cel Ther* 2(2): 354-357.